MDM2 and neuroblastoma: In addition, combining MDM2 antagonists with other drugs or experimental compounds has the potential to enhance therapeutic outcomes and offer a more effective treatment strategy, ultimately leading to reduced relapse rates in neuroblastoma patients.28